Ivabradina Farmoz

Ivabradine, the active ingredient in Ivabradina Farmoz, is a If‑channel inhibitor presented as an oral dosage form for oral use. It reduces heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients with symptomatic disease.

GNH USA supplies Ivabradina Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Ivabradine acts on the cardiac If‑channel to lower heart rate, providing therapeutic benefit in angina and heart failure.

Chronic stable angina: decreases frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers heart rate, which can improve symptoms and reduce hospitalization risk. Ischemic heart disease (symptomatic): helps control heart rate and relieve chest discomfort.

Ivabradina Farmoz may be associated with several adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena often reported as bright spots. - Bradycardia: heart rate falls below the prescribed range, potentially causing fatigue. - Headache: mild to moderate intensity, commonly occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Severe bradycardia leading to syncope or fainting episodes. - Atrial fibrillation: irregular rapid heart rhythm requiring medical attention. - Symptomatic hypotension: marked drop in blood pressure causing weakness. - Visual impairment (retinal): rare cases of blurred vision or visual field changes.

Before prescribing Ivabradina Farmoz, clinicians should consider several safety measures. - Cardiovascular assessment: evaluate baseline heart rate and rhythm before initiating therapy. - Monitor heart rate: regularly check pulse to ensure it remains above the recommended minimum. - Concomitant bradycardic agents: avoid or adjust dose when used with beta‑blockers, digoxin, or non‑dihydropyridine calcium‑channel blockers. - Hepatic impairment: use with caution in patients with moderate to severe liver dysfunction. - CYP3A4 inhibitors: avoid strong inhibitors such as ketoconazole or clarithromycin. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Ivabradina Farmoz can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma levels and cause excessive bradycardia. - Co‑administration with other heart‑rate‑lowering drugs (beta‑blockers, digoxin, non‑dihydropyridine calcium‑channel blockers): risk of severe bradycardia and atrioventricular block. - Quinidine: can potentiate ivabradine effects and lead to marked heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (diltiazem, verapamil): may require dose adjustment and close monitoring of heart rate. - CYP3A4 inducers (rifampicin, carbamazepine, phenytoin): may reduce ivabradine exposure and diminish efficacy. - Diuretics causing electrolyte imbalance: monitor electrolytes as shifts may affect cardiac conduction.